THE EFFECT OF TYPE AND DOSE OF ANTI-INFLAMMATORY DRUGS ON THE VIABILITY AND OSTEOGENIC POTENTIAL OF DENTAL PULP STEM CELLS

Mohamed R. Elmansy*, Menatalla M. Elhindawy** and Mohamad E. Helal***

ABSTRACT

Objectives: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) after regenerative surgeries may affect the behavior of stem cells used during the treatment. This study investigates the possible effect of NSAIDs on the proliferation and the osteo-differentiation of dental pulp stem cells (DPSCs) in vitro.

Methods: DPSCs were isolated, cultured and characterized with human antibodies CD90, CD105 and CD45. Cells were cultured for a period of 1, 3 and 5 days to assess the viability using different drug concentrations of acetylsalicylic acid (ASA) 10, 50, and 200 μg/mL, Diclofenac sodium 10^{-4} and 10^{-6} M and Meloxicam 0.01, 0.1, and 1 μM. Selected concentration of ASA 10 μg/mL, Diclofenac sodium 10^{-6} M and Meloxicam 0.1 μM were used during osteo-differentiation of the cells.

Results: DPSCs viability assay recorded the highest absorption rate on the 1st day with ASA 10 μg/mL and on the 3rd day with Meloxicam 0.01 μM. On day 5 all concentration of ASA and Diclofenac reported the highest absorption rates. The highest values of calcium compounds was expressed with ASA 10 μg/mL on the 7th day using alizarin red satin.

Conclusion: Using different types of NSAIDs during the postsurgical regimen can affect the viability and osteo-differentiation of DPSCs.

KEY WORDS: Dental pulp stem cells, regenerative medicine, analgesics, viability, osteo-differentiation.

INTRODUCTION

Tissue damage after surgical intervention triggers coagulation, inflammation and then healing. The healing and regenerative capacity of tissues depend on their stem cell population, which has self-renewal capability and the ability to differentiate into specialized cells.1 Thorough out the healing process, the health care practitioner has...
to control the pain and inflammation postoperative, hence the use of nonsteroidal anti-inflammatory drugs (NSAIDs).\textsuperscript{2}

NSAIDs are a diverse group of compounds with similar biological capabilities, pain is relieved mainly by blocking cyclooxygenase-2 (COX-2) mostly in the central nervous system, but not much in the rest of the body. It can be classified as selective or non-selective COX inhibitors.\textsuperscript{3}

NSAIDs became popular as a part of the pain control regimen if not the first choice in acute pain. According to research 60\% of patients respond well to any NSAIDs and 40\% will respond to another type NSAID. The effect of NSAIDs manifests itself very soon after the patient had consumed them and the full effect occurs within one week.\textsuperscript{4} NSAIDs are safe, well tolerated and are considered the first choice among analgesics for patients undergoing surgical procedures but they can delay or impair bone healing at certain critical stages in the healing process.\textsuperscript{5}

Dental pulp stem cells (DPSCs) are colonies of highly proliferative fibroblastic-like shaped cells with high frequency of colony-forming and a high rate of proliferation.\textsuperscript{5} They have the ability to differentiate into at least 3-cell lineages odontogenic/ osteogenic, neurogenic and adipogenic, confirming their mesenchymal identity.\textsuperscript{7}

Mesenchymal stem cells (MSCs)- derived from bone marrow- have been proven to prevent the expression of pro-inflammatory cytokines such as interferon- γ “IFN- γ” and tumor necrosis factor-α “TNF- α”.\textsuperscript{8} Cell to cell contact of MSCs with periodontal ligament fibroblast in vitro had an immunomodulatory influence on terminating the inflammatory process during healing.\textsuperscript{9} Also the use of bone marrow MSCs in treating rheumatoid arthritis proved to suppress the inflammatory cytokines.\textsuperscript{10} Transplantation of DPSCs in diabetic rats modulated the proportions of macrophages and produced abundant immunomodulatory cytokines indicating its important role in the anti-inflammatory effects of the treatment of diabetic polyneuropathy.\textsuperscript{11}

Regenerative medicine and tissue engineering aim to restore structure and function of tissues and organs\textsuperscript{12} through the combined use of stem cells, bio-scaffold and growth factors.\textsuperscript{13} In the oral and maxillofacial region, bone regeneration and repair are of interest. Mandibular bone defects were repaired using collagen sponge scaffold and DPSCs harvested from the third molars of the patient.\textsuperscript{14} Stem cells with osteogenic potentials provided accelerated bone formation in large alveolar bone defects as well as enhanced osseointegration in dental implant treatments.\textsuperscript{15}

Drug administration for pain relief after surgical procedures is the most controllable factor, because their impact on bone healing can accounted for depending on choice and dosage.\textsuperscript{5}

Understanding the influence of different types of NSAIDs on DPSCs proliferative and osteo-differentiation potentials in vitro is important for the implantation of regenerative medicine in the oral and maxillofacial region.

MATERIALS

Chlorhexidine (Kenara mouthwash; Macro Group Pharmaceuticals)

Phosphate buffered saline (PBS, Gibco)

Dulbecco’s Modified Eagle Media- Ham’s F12 (DMEM/F12; Lonza)

Fetal Bovine Serum (FBS) (Gibco)

Penicillin and streptomycin (Pen/Strip) (Gibco)

Trypsin EDTA (ThermoFisher SCINTIFIC)

acetylsalicylic acid (ASA) (Sodium salt powder purchased from EL Nasr Pharmaceutical Chemical Company, Cairo, Egypt)

Diclofenac sodium (Novartis Pharma AG, Basel, Switzerland)

Meloxicam (Adwia Pharmaceuticals Co., Egypt)
METHODS

Isolation of DPSCs

DPSCs were isolated from chronic inflamed soft tissue impacted lower third molar that was indicated for extraction from young healthy patients. Patient consent was obtained through the Ethics committee of Faculty of Dentistry, Mansoura University, Egypt. The extraction procedures were held in the Oral Surgery department, Faculty of Dentistry, Mansoura University, Egypt under severe sterilization protocol. Extracted teeth were disinfected by immersion in chlorhexidine for 2 minutes in sterile falcon tubes then were removed with a sterile tweezer to another set of sterile falcon tubes containing phosphate buffered saline. The extracted teeth were then transported in the PBS’s to laminar flow hood where the teeth were crushed using a Hand Held Pulp Isolator device. The pulp tissue was excavated with small sterile excavator then minced into small fragments by two opposing scalpels moving in a cross manner.

Growth of HDPSCs

Pulp pieces were cultured in 25 cm² flask (Greiner) with 10 ml Dulbecco’s Modified Eagle Media - Ham’s F12 supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin and streptomycin (Pen/Strip). The cultured pieces were then incubated at 37°C and 5% CO² atmosphere.

Complete Media (CM) (DMED/F12 + FBS + Pen/strip) was replaced every three days. The first passage was performed when monolayer of adherent cells reached 70-80% confluence. Feeding continued with the protocol of cell culturing until the cells reached 4th passage when they were ready to be used. During passaging, cells were de-adhered with trypsinization process.

Flow cytometry analysis of HDPSCs

At the 4th passage cells were characterized using cell surface antigen expressions: DPSCs were detached by 0.5 mL of % 0.25 trypsin EDTA and washed with PBS followed by incubation with antibodies for human CD90 phycoerythrin (PE), CD105 PE and CD45 fluorescein isothiocyanate (FITC) at 4°C for 30 minutes. Acquisition and analysis for CD105 and CD90 were performed with a BD Accuri C6 flow cytometer and for CD 45 were done by fluorescein activated cell sorting {FACS Canto, BD, USA} and the data analyzed with BD Cell Quest™ Pro version C6.0 software (BD, USA).

Assessment of cell viability

DPSCs were seeded at 2.5×10⁴ cells/well in a 96 well plate at a final volume of 100 µL of CM and cultured overnight at 37°C and 5% CO². Following that, cells were divided into control group cultured in CM only and experimental groups cultured with different concentrations of ASA 10, 50, and 200µg/mL, Diclofenac sodium 10⁻⁴ and 10⁻⁶ M and Meloxicam 0.01, 0.1, and 1 µM for 1, 3 and 5 days (3 wells for each concentration in each time period for all groups). At the end of the treatment 100µL of 3-(4, 5-dimethyl thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium inner salt (MTS; Promega) were added to the plates. Absorbance was measured at 490 nm with a spectrophotometer (Thermo fisher scientific, Waltham, MA, USA). (Table 1)

Osteogenic differentiation assay

To induce mineralization, DPSCs were seeded at 2x10⁴ cells/well in the 6 well plates and treated with osteogenic differentiating media containing nutritional media (DMEM-F12), 50 µg/ml of L-ascorbic acid 2-phosphate, 10 mM of β-glycerophosphate sodium salt, 0.1 µM of dexamethasone, antibiotics (100 mg/ml streptomycin and 100 µ/ml Penicillin-G) and 10% FBS. NSAIDs were added to the media with selected concentrations ASA 10 µg/mL, Diclofenac sodium 10⁻⁶ M and Meloxicam 0.1 µM. The cells were maintained in osteogenic differentiation media for 7 days and the
media renewed every 3 days. After the 7th day, a quantified analysis was conducted by Alizarin red-based assay, 10% buffered formalin for 10 minutes and stained with 2% alizarin red S (Wako, Osaka, Japan) for 15 minutes at room temperature so that the mineral matrix of the bone could be observed. The intensity of calcium compound staining was evaluated by MTT assay measured with optical density at 405 nm (ELISA reader).

DPSCs cultured with no osteogenic medium were used as control negative group and DPSCs cultured with osteogenic medium were used as control positive group. (Table 1)

TABLE (1): Showing experimental groups.

<table>
<thead>
<tr>
<th>Experimental Groups</th>
<th>Viability potential</th>
<th>Osteogenic differentiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA Group</td>
<td>10 µg/mL</td>
<td>10 µg/mL group</td>
</tr>
<tr>
<td></td>
<td>50 µg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200 µg/mL</td>
<td></td>
</tr>
<tr>
<td>Diclofenac sod.</td>
<td>10^-4 M</td>
<td>10^-6 M group</td>
</tr>
<tr>
<td>Group</td>
<td>10^-6 M</td>
<td></td>
</tr>
<tr>
<td>Meloxicam group</td>
<td>0.01 µM</td>
<td>0.1 µM</td>
</tr>
<tr>
<td></td>
<td>0.1 µM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 µM</td>
<td></td>
</tr>
</tbody>
</table>

RESULTS

Cell culture

Cultures were observed using inverted light microscope; they appeared rounded and floating on the 5th day of isolation. Two weeks after isolation, the cells took a spindle shape and were interlaced with each other. The primary culture reached 70-80% of confluence after 3 weeks of isolation and cells were moved to the 2nd passage by trypsinization. (Fig. 1)

Flow cytometry analysis

Surface antigen analysis for DPSCs at the 4th passage revealed that cells were positive to CD90 (72.6±0.1) and CD105 (70.06±0.19) while cells expressed negative results (10.1±0.9) for the hematopoietic marker (CD45). (Fig 2)

Assessment of cell viability

In the control and NSAID- treated cells, cell viability was determined by rate of absorption of MTS agent. On the 1st day, the highest rate of absorption among ASA concentrations was recorded with 10 µg/mL (1.95±0.1). In Diclofenac, the highest absorption was recorded at 10^-6 concentration (2.01±0.05) and in Meloxicam the highest rate was recorded was at 0.01 µM concentration (1.31±0.02). The highest absorption rate was recorded on the 3rd day with Meloxicam at 0.01 µM concentration (2.16±0.01). The highest values in ASA 10 µg/mL concentration and Diclofenac 10^-4 M concentration were (1.65±0.04) and (1.66±0.11) respectively. On the 5th day, both ASA and Diclofenac concentrations recorded higher absorption rates when compared to Meloxicam concentrations. (Table 2).

Osteogenic differentiation assay

Mineralization capability for DPSCs treated with selected concentrations of NSAID was measured with alizarin red staining. ASA 10 µg/mL shows large red area with traces of minute deposits, Diclofenac sodium 10^-6 M shows different separated
red deposits while Meloxicam 0.1 μM showed the least deposits. The intensity of calcium compound by MTT assay confirmed the quantified analysis by alizarin red: ASA 10 μg/mL showed the highest rate of absorption (0.26±0.01), followed by Diclofenac sodium 10⁻⁶ M (0.18±0.08). The least absorption rate recorded was Meloxicam 0.1 μM (0.13±0.01). (Fig 3)

Fig. (1) Inverted light microscopic images showing DPSCs colony formation capacity A) Isolated DPSCs, B) Isolated HDPSCs after incubation for 7 days, C) after 2 weeks, D) 1 day after 1st passage and E) after 3 weeks. (original magnification x10)
Statistical analysis

One-way ANOVA for proliferation MTS assay for different concentration NSAIDs revealed that ASA 10 μg/mL concentration showed significant difference than the control group, 50 μg/mL and 200 μg/mL concentration on the 1st day. The difference was significant at 200 μg/mL concentration only on the 3rd and 5th days. ASA 50 μg/mL was significant to the control group on the 3rd day and to 200 μg/mL concentration on the 5th day. ASA 200 μg/mL was significant to 10 μg/mL concentration at all times and to control on 3rd and 5th days and to 50 μg/mL at the 5th day only. Both 10⁻⁴ M and 10⁻⁸ M concentrations of Diclofenac showed significant difference to each other and to control group only on the 1st day. Also 0.01 μM, 0.1 μM and 1 μM concentrations of Meloxicam were significant to each other and to control group only on the 3rd day (Table 3).

As for osteogenic differentiation, ASA 10 μg/mL group showed a significant difference to control positive group, Meloxicam 0.1 μM group and Diclofenac sodium 10⁻⁶ M group. Diclofenac sodium 10⁻⁶ M group revealed a significant difference to Meloxicam 0.1 μM only while Meloxicam 0.1 μM group showed a significant difference for control positive group (Table 4).

Fig 2: Flow cytometric analysis showing DPSCs positive for CD90 and CD105 negative for CD 45.
Fig 3: Inverted light microscopic images showing osteogenic capability of DPSCs after 7 days (A) control positive group, (B) ASA 10 μg/mL, (C) Diclofenac sodium 10-6 M, (D) Meloxicam 0.1 μM. (Alizarin red stain, original magnification x10)

TABLE (2) Comparison between Control & NSAIDs concentrations different time periods

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
<th></th>
<th>Day 3</th>
<th></th>
<th>Day 5</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>±SD</td>
<td>Mean</td>
<td>±SD</td>
<td>Mean</td>
<td>±SD</td>
</tr>
<tr>
<td>Control group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA Group 10 μg/mL</td>
<td>1.950</td>
<td>0.100</td>
<td>1.652</td>
<td>0.043</td>
<td>2.408</td>
<td>0.188</td>
</tr>
<tr>
<td>ASA Group 50 μg/mL</td>
<td>1.778</td>
<td>0.152</td>
<td>1.582</td>
<td>0.052</td>
<td>2.463</td>
<td>0.052</td>
</tr>
<tr>
<td>ASA Group 200 μg/mL</td>
<td>1.741</td>
<td>0.089</td>
<td>1.540</td>
<td>0.026</td>
<td>2.076</td>
<td>0.093</td>
</tr>
<tr>
<td>Diclofenac sod. Group 10^-4 M</td>
<td>1.850</td>
<td>0.088</td>
<td>1.660</td>
<td>0.110</td>
<td>2.246</td>
<td>0.134</td>
</tr>
<tr>
<td>Diclofenac sod. Group 10^-6 M</td>
<td>2.017</td>
<td>0.057</td>
<td>1.587</td>
<td>0.009</td>
<td>2.418</td>
<td>0.095</td>
</tr>
<tr>
<td>Meloxicam group 0.01 μM</td>
<td>1.314</td>
<td>0.024</td>
<td>2.167</td>
<td>0.011</td>
<td>1.805</td>
<td>0.057</td>
</tr>
<tr>
<td>Meloxicam group 0.1 μM</td>
<td>1.263</td>
<td>0.079</td>
<td>2.274</td>
<td>0.012</td>
<td>1.898</td>
<td>0.095</td>
</tr>
<tr>
<td>Meloxicam group 1 μM</td>
<td>1.247</td>
<td>0.031</td>
<td>2.378</td>
<td>0.044</td>
<td>1.878</td>
<td>0.036</td>
</tr>
</tbody>
</table>
TABLE (3) Significant differences between all NSAIDs concentrations at different time periods

<table>
<thead>
<tr>
<th>Group</th>
<th>10 μg/mL</th>
<th>50 μg/mL</th>
<th>200 μg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASA Group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>0.038*</td>
<td>0.99</td>
<td>0.96 , 0.93</td>
</tr>
<tr>
<td>Day 3</td>
<td>0.56</td>
<td>0.02</td>
<td>0.01*, 0.93</td>
</tr>
<tr>
<td>Day 5</td>
<td>0.67</td>
<td>0.29</td>
<td>0.001*, 0.65</td>
</tr>
<tr>
<td><strong>Diclofenac sod.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10^-4 M</td>
<td>0.15</td>
<td>-</td>
<td>0.15</td>
</tr>
<tr>
<td>10^-6 M</td>
<td>&lt;0.001*</td>
<td>0.003*</td>
<td>0.01*</td>
</tr>
<tr>
<td><strong>Meloxicam group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 μM</td>
<td>0.3</td>
<td>-</td>
<td>0.3</td>
</tr>
<tr>
<td>0.1 μM</td>
<td>0.3</td>
<td>&lt;0.001*</td>
<td>0.3</td>
</tr>
<tr>
<td>1 μM</td>
<td>0.3</td>
<td>&lt;0.001*</td>
<td>0.3</td>
</tr>
</tbody>
</table>

P1: significance relative to Control group  
P2: significance relative to ASA10  
P3: significance relative to ASA50  
P4: significance relative to DIC 10^-4 group  
P5: significance relative to 0.01 μM Meloxicam group  
P6: significance relative to 0.1 μM Meloxicam group

TABLE (4) Comparison of osteogenic capability of dental pulp stem cells between different studied groups

<table>
<thead>
<tr>
<th></th>
<th>Control negative group</th>
<th>Control positive group</th>
<th>Meloxicam 0.1 μM group</th>
<th>Diclofenac sodium 10^-6 M group</th>
<th>ASA 10 μg/mL group</th>
</tr>
</thead>
<tbody>
<tr>
<td>osteogenic capability</td>
<td>.282 ±.036</td>
<td>.194 ±.032</td>
<td>.133 ±.018</td>
<td>.189 ±.008</td>
<td>.268 ±.012</td>
</tr>
</tbody>
</table>

P1: significance relative to Control negative group  
P2: significance relative to Control Positive group  
P3: significance relative to 0.1 μM Meloxicam group  
P4: significance relative to 10^-6 M Diclofenac sodium group
DISCUSSION

Tissue engineering is a promising solution for tissue and organ reconstruction and transplantation of newly formed bone chips obtained in vitro. The real challenge was to have DPSCs planted into a scaffold developed into well vascularized adult human bone.\textsuperscript{17}

Drugs have an impact on bone healing and repair and although the choice and dosage of analgesics can be controlled, the use of NSAIDs cannot be controlled as much. NSAIDs are the most often used drugs, not only in prescription but also as self-medication to control both pain and inflammation.\textsuperscript{18}

In the current study, DPSCs isolated from the third molar and cultured in culture media showed positive expression to surface markers CD 90 and CD 105 but negative expression to CD 45. The results were in agreement with the International Society of Cellular Therapy (ISCT) 2006 which stated that MSCs must express CD 90 and CD 105 but lack expression of CD 45.\textsuperscript{19}

Our results also showed that ASA concentrations 10 and 50 μg/mL enhanced the proliferation of DPSCs, while a higher dose 200 μg/mL had no effect. Also the osteogenic capability of the DPSCs was enhanced with ASA at 10 μg/mL concentration. These results are in agreement with Liu et al. 2015, who found that ASA at 10-50 μg/mL concentrations promoted proliferation and osteogenic differentiation of stem cells derived from deciduous teeth. The researchers attributed this findings to low dose of ASA which enhanced the activity of telomerase which in extend the stem cells life span and improve their functions.\textsuperscript{20}

In contrary to our results, Abd Rahman et al. 2016 stated that ASA concentrations 10 μg/mL to 200 μg/mL had an inhibitory effect on proliferation of periodontal ligament stem cells.\textsuperscript{21} Also Cao et al. 2015 reported that ASA concentrations 100 to 150 μg/mL display an inhibitory effect on proliferation of swine bone marrow stem cells.\textsuperscript{22}

Regarding osteogenic differentiation of periodontal ligament stem cells Abd Rahman et al. 2016 reported that ASA concentrations 10 and 200 μM reduced osteogenic differentiation on days 7 due to the inhibition of growth factors as Runx-related transcription factor 2 (RUNX2). RUNX2 upregulation causes various events that eventually lead to the expression of osteogenic proteins.\textsuperscript{21}

In the present study, Diclofenac sodium at concentration 10\textsuperscript{-6} M and 10\textsuperscript{-4} showed positive proliferative effect on DPSCs. Also, it promoted the osteogenic ability of DPSCs at concentration 10\textsuperscript{-6} M. These findings are in contradict with Chang et al.’s 2007 who stated that NSAIDs such as Diclofenac sodium suppress the proliferation but not the osteogenesis of mesenchymal stem cells at the therapeutic doses.\textsuperscript{23}

Our study found that 0.1 and 1 μM Meloxicam showed more cell proliferation on the 3\textsuperscript{rd} day than other time periods. The osteogenic capability of cells treated with 0.1 μM Meloxicam was the lowest when compared to other NSAIDs. These results are in agreement with Muller et al. 2011 who reported that Meloxicam concentrations from 0.01 to 10 μM induced more marked increasing effects on equine mesenchymal stem cell proliferation. Also Meloxicam of 1 μM concentration showed negative effects on osteogenic differentiation capability.\textsuperscript{16}

Our data show that the use of therapeutic concentrations of NSAIDs have an effect on DPSCs capability of proliferation and cell growth as well as on its osteogenic differentiation. As a matter of fact, those therapeutic concentrations can be used to promote the proliferation at certain periods.

Although there is growing evidence of the anti-inflammatory properties of stem cell therapy, there is no evidence on its ability to replace or reduce the use of pain killers and analgesics with anti-inflammatory properties after surgical intervention.
RECOMMENDATION

The choice of the appropriate NSAID in the intervention of a stem cell-based therapy is critically important. According to our data, shifting from one drug to another may enhance the proliferation and osteo-differentiation of the cells. The study recommends to use of Diclofenac sodium $10^{-9}$ M as a potent drug of choice in the 1st day postoperative followed by Meloxicam 0.1 $\mu$M from the 3rd day to avoid peptic ulceration then continue the treatment with ASA 10 $\mu$g/mL starting from the 5th day.

ACKNOWLEDGMENT

We would like to thank Ahmed Shetewy, Faculty of Dentistry, Mansoura University for his device “Hand Held Pulp Isolator”. We also would like to thank Medical Experimental Research Center of Mansoura University (MERC) for their continuous support.

REFERENCES


8. Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel. Published online 2008:569-582.


10. F HAA, F ASA. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Published online 2018. doi:10.17219/acem/73720


